All In Biotech

Drug Trial Radar · NCT04741542

Safety of SP-420 in the Treatment of Transfusional Iron Overload

Phase 1, Open-Label, Dose Escalation Study to Assess the Safety of SP-420 in the Treatment of Transfusional Iron Overload

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Mar 9, 2021

Primary completion

Jan 10, 2024

Study completion Jan 10, 2024

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Abfero Pharmaceuticals, Inc
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is poor due to problems related to ease of administration, tolerability, and safety.

Conditions

  • Iron Overload

Interventions

  • SP-420Drug

    This study aims to establish the safety of SP-420 administered orally three times per week (TIW).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse eventsTime frame: 28 Days
  2. Completion at original doseTime frame: 28 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mays Cancer Center, UT Health San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.